Theialife Sciences

1:45 PM - 2:00 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 103

Virtual Clinical stage (Phase 3 ready) Ophthalmology focused company with a lead molecule for pediatric myopia control. Post phase 2 clinical trials we have completed 12 years of real world clinical usage in Denmark and have treated over 1200 children. Our research was published in the British Journal of Ophthalmology in August 2022. Our IP remains intact for future 20 years. Dose and dosing is twice daily from diagnosis to late teen age years.